Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 3

Status

Recruiting 4Active not recruiting 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 3Gynecologic 2Breast 2Thoracic 1

Conditions

Prostatic Neoplasms 3Ovarian Neoplasms 2Endometrial Neoplasms 2Neoplasms 1Breast Neoplasms 1Advanced Breast Cancer 1Adenocarcinoma of Lung 1

Interventions

Specimen Handling 278Magnetic Resonance Spectroscopy 233pembrolizumab 227Carboplatin 187Cisplatin 153Biopsy 148Cyclophosphamide 143Paclitaxel 133Nivolumab 122Gemcitabine 113Bevacizumab 104Radiotherapy 92Dexamethasone 86Pemetrexed 83fludarabine 77Fluorouracil 76Docetaxel 75Doxorubicin 74atezolizumab 71Radiation 71Leucovorin 70Rituximab 67Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 60Vincristine 56Cetuximab 56Lenalidomide 54Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × AZD5305 × 30 days × Clear all
NCT05797168 2026-06-03

FONTANA

AstraZeneca

Phase 1/2 Recruiting
506 enrolled
GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT05367440 2026-06-01

PETRANHA

AstraZeneca

Phase 1/2 Active not recruiting
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT06120491 2026-05-27

EvoPAR-PR01

AstraZeneca

Phase 3 Active not recruiting
1,889 enrolled
Genitourinary

Prostatic Neoplasms

NCT06952803 2026-05-19

EvoPAR-PR02

AstraZeneca

Phase 3 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting
500 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡